Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000563438 | SCV000662282 | uncertain significance | Hereditary cancer-predisposing syndrome | 2016-03-22 | criteria provided, single submitter | clinical testing | Lines of evidence used in support of classification: In silico models in agreement (deleterious) and/or completely conserved position in appropriate species,Insufficient or conflicting evidence |
| Invitae | RCV000629938 | SCV000750894 | uncertain significance | Hereditary nonpolyposis colon cancer | 2017-12-10 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine with threonine at codon 708 of the MSH2 protein (p.Ile708Thr). The isoleucine residue is highly conserved and there is a moderate physicochemical difference between isoleucine and threonine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with MSH2-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Color | RCV000563438 | SCV000906773 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-10-03 | criteria provided, single submitter | clinical testing |